Menu

MedTech and Pharma News



New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Pink Sheet - January 22, 2020
Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the...
In Vivo - January 22, 2020
ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure...
In Vivo - January 22, 2020
Polish Industry Fighting Against Advertising Tax On Supplements
Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the...
HBW Insight - January 22, 2020
England’s NICE Future Proofs Approach To Using Data
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its...
Pink Sheet - January 22, 2020
Diagnostics Sector On High Alert As Wuhan Coronavirus Spreads
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up...
Medtech Insight - January 22, 2020
Horizon Sees Blockbuster Future For Tepezza After US Approval
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Scrip - January 22, 2020
Medicinal Products Expert And Established Devices Leader Head Commission’s Medtech Unit
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He...
Medtech Insight - January 22, 2020
Bayer receives US license to Dare’s vaginal contraceptive ring Ovaprene
Dare Bioscience Inc. licensed Bayer AG US rights to its investigational vaginal silicone ring Ovaprene.
Strategic Transactions - January 22, 2020
Osmotica nets $28mm through FOPO
Osmotica Pharmaceuticals PLC (specialty extended-release generics) netted $28mm through the public offering of 6mm ordinary shares at $5. In November 2019, Osmotica announced the FDA accepted its NDA filing for RVL1201 (oxymetazoline hydrochloride) ophthalmic solution, 0.1% for acquired blepharoptosis (droopy eyelid or ptosis) with a PDUFA goal date of July 16, 2020.
Strategic Transactions - January 22, 2020
QUOTED. 22 January 2020. Steve Niedelman.
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called...
Medtech Insight - January 22, 2020

Diagnostics Sector On High Alert As Wuhan Coronavirus Spreads
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up...
Medtech Insight - January 22, 2020
Medicinal Products Expert And Established Devices Leader Head Commission’s Medtech Unit
Erik Hansson remains deputy head of devices in a move to the European Commission’s DG Sante from DG Grow. He...
Medtech Insight - January 22, 2020
QUOTED. 22 January 2020. Steve Niedelman.
Steve Niedelman of the law firm King & Spalding gave manufacturers a few words of advice when prepping their so-called...
Medtech Insight - January 22, 2020

Horizon Sees Blockbuster Future For Tepezza After US Approval
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Scrip - January 22, 2020

New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
Pink Sheet - January 22, 2020
England’s NICE Future Proofs Approach To Using Data
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its...
Pink Sheet - January 22, 2020

Connected Strategies Are Vital For Medtechs In The Consumer-Led 2020s
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the...
In Vivo - January 22, 2020
ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure...
In Vivo - January 22, 2020

Bayer receives US license to Dare’s vaginal contraceptive ring Ovaprene
Dare Bioscience Inc. licensed Bayer AG US rights to its investigational vaginal silicone ring Ovaprene.
Strategic Transactions - January 22, 2020
Osmotica nets $28mm through FOPO
Osmotica Pharmaceuticals PLC (specialty extended-release generics) netted $28mm through the public offering of 6mm ordinary shares at $5. In November 2019, Osmotica announced the FDA accepted its NDA filing for RVL1201 (oxymetazoline hydrochloride) ophthalmic solution, 0.1% for acquired blepharoptosis (droopy eyelid or ptosis) with a PDUFA goal date of July 16, 2020.
Strategic Transactions - January 22, 2020

Polish Industry Fighting Against Advertising Tax On Supplements
Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the...
HBW Insight - January 22, 2020
Back to the top Back to the top